Neils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada.

U.S. equities declined to start the month on uncertainty about the future of Trump administration tariffs. The S&P 500 and Nasdaq lost nearly 1%, and the Dow Jones Industrial Average slipped as well.

United Therapeutics Corporation (NASDAQ:UTHR) shares surged more than 35% following the release of positive late-stage clinical trial results for its lung disease drug Tyvaso. The company said its TETON-2 study evaluating nebulized Tyvaso in patients with idiopathic pulmonary fibrosis (IPF) met its primary endpoint, showing significant improvements in lung function compared with placebo over a 52-week period.

First Solar lifts its 2025 sales outlook after beating Q2 earnings and revenue estimates, fueling investor optimism despite industry risks.

AI revenue grew 220% year-on-year, propelled by their leading XPUs and Ethernet networking portfolio.

The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth.

Signet Jewelers Limited reported strong earnings momentum in Q2, enabled by a sharp increase in pricing as the company has lowered promotions and improved the assortment. Even the raised FY2026 guidance suggests earnings pressure ahead. Signet's long-term outlook remains pressured by lab-grown diamonds. I estimate SIG stock to have 16% downside to $72.7 in a base scenario.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Positive CORE and CORE2 Topline Results Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Sotirios Tsimikas - Senior Vice President of Global Cardiovascular Development Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jason Gerberry - BofA …

Key Points SoundHound AI (SOUN) develops voice and conversational AI solutions for automotive, QSR, and enterprise sectors, with rapid adoption by brands like Hyundai, Chipotle Mexican Grill, and Stellantis.

RKLB doubles down on semiconductor production to strengthen its role in space and defense technologies.

AMZN bets big on AWS growth with a NZ$7.5B New Zealand region launch, fueling AI, compliance and APAC expansion.

DHR posts gains in bioprocessing, biotech and diagnostics, while life sciences softness and high debt weigh.

JPMorgan, Goldman Sachs, and Citigroup gain as bank stocks surge on Fed signals, strong earnings and stress test resilience.

YPrime, a proven leader in clinical trial technology, today announced it has been recognized as a Leader in the Everest Group's Life Sciences Electronic

Cytokinetics, Incorporated -Exploring The Changing Treatment Paradigm Transcript Company Participants Diane Weiser - Senior Vice President of Corporate Affairs Fady Malik - Executive Vice President of Research & Development Daniel Jacoby Robert I. Blum - CEO, President & Director Conference Call Participants Pablo García-Pavia - Head, Heart Failure and Inherited Cardiac Diseases Unit, Hospital Universatario Carolyn Ho - Medical Director of the Cardiovascular Genetic Center Ahmad Masri - Cardiomyopathy Section Head and Director, Hypertrophic Cardiomyopathy Center Anjali Owens - Medical Director, Inherited Cardiac Disease Presentation Diane Weiser Senior Vice President of Corporate Affairs Welcome, everyone, and thanks for joining.

D-Wave debuts a PyTorch-integrated Quantum AI toolkit, but IBM and Google's hardware breakthroughs keep the pressure on.

Marvell Technology posts 69% data center revenue surge as AI chip demand and optics innovation drive growth momentum.

SIG beats second-quarter expectations and updates fiscal 2026 outlook higher as same-store sales rise and margins expand.

Salesforce trails its tech large-cap peers and is the second-worst performer in the Dow this year, ahead of only UnitedHealth. The company's growth rate has been below 10% since mid-2024, and analysts don't expect revenue growth to reach double digits for the latest quarter.

For years, Elon Musk has spoken of the promise of Dojo, the AI supercomputer that was supposed to be the cornerstone of Tesla's AI ambitions. It was important enough to Musk that in July 2024, he said the company's AI team would “double down” on Dojo in the lead-up to Tesla's robotaxi reveal, which happened in October.